Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1073445 10.3389/fphar.2022.1073445 Pharmacology Correction Corrigendum: Adenosine receptor stimulation by polydeoxyribonucleotide improves tissue repair and symptomology in experimental colitis Pallio et al. 10.3389/fphar.2022.1073445 Pallio Giovanni 1 Bitto Alessandra 1 * Pizzino Gabriele 1 Galfo Federica 1 Irrera Natasha 1 Squadrito Francesco 1 Squadrito Giovanni 2 Pallio Socrate 1 Anastasi Giuseppe P. 3 Cutroneo Giuseppina 2 Macrì Antonio 2 Altavilla Domenica 3 1 Section of Pharmacology, Department of Clinical and Experimental Medicine, Medical School, University of Messina, Messina, Italy 2 Department of Human Pathology, University of Messina, Messina, Italy 3 Department of Biomedical Sciences and Morphological and Functional Images, University of Messina, Messina, Italy

Approved by: Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland

 *Correspondence: Alessandra Bitto, abitto@unime.it

This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology

 10 11 2022 2022 13 1073445 18 10 2022 19 10 2022 Copyright © 2022 Pallio, Bitto, Pizzino, Galfo, Irrera, Squadrito, Squadrito, Pallio, Anastasi, Cutroneo, Macrì and Altavilla. 2022 Pallio, Bitto, Pizzino, Galfo, Irrera, Squadrito, Squadrito, Pallio, Anastasi, Cutroneo, Macrì and Altavilla

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Adenosine receptor stimulation by polydeoxyribonucleotide improves tissue repair and symptomology in experimental colitis by Pallio G, Bitto A, Pizzino G, Galfo F, Irrera N, Squadrito F, Squadrito G, Pallio S, Anastasi GP, Cutroneo G, Macrì A and Altavilla D (2016). Front. Pharmacol. 7:273. doi: 10.3389/fphar.2016.00273 colitis A2A agonist PDRN inflammation apoptosis

In the published article, the Conflict of Interest statement was incorrectly filed. The correct Conflict of Interest statement appears below.

“Author FS has received research support from Mastelli for work on polydeoxyribonucleotide. Authors FS, AB and DA are co-inventors on a patent describing therapeutic polydeoxyribonucleotide activity in chronic intestinal disease.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.